Prostate Cancer

Sipuleucel-T (Provenge) was associated with a median overall survival of 47.7 months in a subgroup of patients with asymptomatic or minimally invasive metastatic castration-resistant prostate cancer.

Manoj K. Jain, MD, discusses the use of radioligand therapy in prostate cancer.

Manish Kohli, MD, vice chair, Department of Genitourinary Oncology, Moffitt Cancer Center, discusses sequencing concerns in metastatic hormone-sensitive prostate cancer (mHSPC).

Manoj K. Jain, MD, discusses new imaging modalities and what they could mean for the field going forward.

Randal Henderson, MD, MBA, discusses the data that led to the PCORI-funded trial, what the results could mean for the field, and interesting research on the horizon.

Manish Kohli, MD, discusses the agents that have redefined the treatment paradigm of metastatic prostate cancer and details ongoing work to elucidate genomic classifiers.

Randal H. Henderson, MD, MBA, professor, Department of Radiation Oncology and associate medical director at the University of Florida Health Proton Therapy Institute, discusses the potential benefits of proton therapy versus intensity-modulated radiation therapy in prostate cancer.

The FDA has granted a priority review designation to a supplemental new drug application for enzalutamide (Xtandi) for the treatment of men with metastatic hormone-sensitive prostate cancer.

Manoj K. Jain, MD, nuclear medicine specialist, radiologist, Mayo Clinic, discusses the indications for PET imaging in prostate cancer.

Randal H. Henderson, MD, MBA, professor, Department of Radiation Oncology, associate medical director, University of Florida Health Proton Therapy Institute, discusses the benefits of proton therapy in prostate cancer.

Seeking to explore an apparent synergy between agents, investigators are evaluating the PARP inhibitor olaparib in combination with the hormone blocker abiraterone in men with metastatic castration-resistant prostate cancer who have received no prior cytotoxic chemotherapy or new hormonal agents.

Winston Tan, MD, hematologist/oncologist, Mayo Clinic, discusses imaging modalities in prostate cancer.

Manoj K. Jain, MD, nuclear medicine specialist, radiologist, Mayo Clinic, discusses new imaging modalities to detect disease in patients with prostate cancer.

Winston Tan, MD, discusses the influx of treatment options in nonmetastatic castration-resistant prostate cancer and the modalities that are being used in an effort to ensure their optimal use.

Nicholas J. Vogelzang, MD, FASCO, FACP, discusses groundbreaking developments that have transformed the treatment of prostate cancer, as well as current issues in urology.

Sipuleucel-T received an FDA approval in 2010 and a subsequent CMS coverage decision in 2011. At Lancaster Urology in Pennsylvania, we began infusing sipuleucel-T in 2011, and at the 7-year mark, we conducted a review to evaluate these first years of therapy.

Daniel J. George, MD, professor of Medicine and Surgery, member, Duke Cancer Institute, discusses the promise of PARP inhibitors in prostate cancer.

Olaparib demonstrated a statistically significant and clinically meaningful improvement in radiographic progression-free survival compared with enzalutamide or abiraterone acetate in patients with metastatic castration-resistant prostate cancer who harbor a homologous recombination repair gene mutation and have progressed on prior therapy with either androgen receptor inhibitor, meeting the primary endpoint of the phase III PROfound trial.

Androgen deprivation therapy (ADT) increases the risk of subsequent Alzheimer disease and dementia among men ≥66 years with prostate cancer, according to findings of a large retrospective study that examined the link between ADT treatment and later cognitive dysfunction.

Walter M. Stadler, MD, Fred C. Buffett Professor of Medicine and Surgery, dean for clinical research, director of the Genitourinary Oncology Program, and deputy director of the Comprehensive Cancer Center, at the University of Chicago Medicine, discusses the use of active surveillance in prostate cancer.